Evidence map›Paper›PMID 31396944›Full record

ReviewDermatology and therapy2019

Topical Non-Pharmacological Treatment for Facial Seborrheic Dermatitis.

Jaime Piquero-Casals, Doris Hexsel, Juan Francisco Mir-Bonafé, Eduardo Rozas-Muñoz

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Dermatology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06361992 (Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06361992 phase3completednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children

TypeinterventionalSponsorCatalysis SLRan2022 to 2024Enrolled58ConditionsAtopic Dermatitis, Atopic Dermatitis and Related Conditions, Atopic Dermatitis Eczema, Atopic Dermatitis \(AD\)ArmsBlue Cap Foam
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. [Piroctone olamine disrupts mitochondrial dynamics in glioma cells through the PI3K/AKT pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. An Overview of the Diagnosis and Management of Seborrheic Dermatitis.Clinical, cosmetic and investigational dermatology · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jaime Piquero-CasalsDepartment of Dermatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain. jaime.piquero@e-campus.uab.cat.ORCID http://orcid.org/0000-0002-4481-5602
Doris HexselBrazilian Center for Studies in Dermatology, Porto Alegre, RS, Brazil.
Juan Francisco Mir-BonaféDepartment of Dermatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
Eduardo Rozas-MuñozDepartment of Dermatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
Hospital de Sant Pau · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Facial seborrheic dermatitis (FSD) is a chronic and relapsing inflammatory skin disorder occurring in areas of the face rich in sebaceous glands. It clinically manifests as erythematous scaly macules or plaques, often associated with pruritus. Although the pathogenesis of seborrheic dermatitis is not yet fully understood, Malassezia yeast, hormones, sebum levels, and immune response are known to play important roles. Additional factors including drugs, cold temperatures, and stress may exacerbate the condition. Currently, the available treatments do not cure the disease but relieve symptoms. Various pharmacological treatments are available, including antifungal agents, keratolytics, topical low-potency steroids, and calcineurin inhibitors. All of them provide several benefits, but they also have potential side effects. Seborrheic dermatitis tends to have a chronic, recurrent course. To avoid the long-term use of drugs, topical non-pharmacological products such as cosmetics or medical devices may improve clinical outcomes. Products with antimicrobial and anti-inflammatory ingredients such as zinc, piroctone olamine, dihydroavenanthramide, biosaccharide gum-2, and stearyl glycyrrhetinate may speed FSD recovery and avoid flare-ups. Finally, the use of specific cleansers, moisturizers, and sunscreens formulated as light creams or gel/creams should be strongly recommended to all FSD patients. We provide a brief review of the most used non-pharmacological cleansers, topical gel/creams, and specific sunscreens in the management of FSD.

Indexed as

CosmeceuticalsCosmeticsFacialMedical deviceSeborrheic dermatitisTopical treatment

Identifiers

PMID31396944
PMCPMC6704200
OpenAlexW2966975237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.